Literature DB >> 19636404

Comparison of Bcl-2, CD38 and ZAP-70 Expression in Chronic Lymphocytic Leukemia.

Rachel L Sargent1, Fiona E Craig, Steven H Swerdlow.   

Abstract

Chronic lymphocytic leukemia (CLL) was previously considered a uniform disease characterized by autonomous over-expression of bcl-2. Recently the pathogenic role of bcl-2 has been questioned and attention has turned to prognostic subtypes of CLL differing in CD38 and ZAP-70 expression. However, the relationship between bcl-2 and CD38 or ZAP-70 expression remains uncertain and was investigated using flow cytometric immunophenotyping of 50 CLL specimens. CLL cells were consistently bcl-2 positive but varied in expression level: mean fluorescence intensity (MFI) 45-152. Although there was no significant difference in bcl-2 expression between CD38 or ZAP-70 positive and negative specimens, an inverse correlation was identified between percentage of CD38 positive B-cells and bcl-2 MFI when all (p<0.03, r(2)=0.10) and peripheral blood (p<0.004, r(2)=0.27) samples were analyzed. While bcl-2 levels do not appear to be a major discriminator between indolent and more aggressive subtypes of CLL, CD38 and bcl-2 expression appear to be interrelated.

Entities:  

Keywords:  CD38; ZAP-70; bcl-2; chronic lymphocytic leukemia

Year:  2009        PMID: 19636404      PMCID: PMC2713455     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  46 in total

1.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

Authors:  Terry J Hamblin; Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Peter W Thomas; Freda K Stevenson; David G Oscier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

Review 2.  Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.

Authors:  Graham Packham; Freda K Stevenson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

3.  CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation.

Authors:  B T Pittner; T D Shanafelt; N E Kay; D F Jelinek
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

Review 4.  In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.

Authors:  Silvia Deaglio; Tiziana Vaisitti; Semra Aydin; Enza Ferrero; Fabio Malavasi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

5.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Authors:  Victoria Del Gaizo Moore; Jennifer R Brown; Michael Certo; Tara M Love; Carl D Novina; Anthony Letai
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

6.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.

Authors:  Rajendra N Damle; Sonal Temburni; Carlo Calissano; Sophia Yancopoulos; Taraneh Banapour; Cristina Sison; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2007-08-07       Impact factor: 22.113

7.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Manuela Ferracin; Amelia Cimmino; Gianpiero Di Leva; Masayoshi Shimizu; Sylwia E Wojcik; Marilena V Iorio; Rosa Visone; Nurettin Ilfer Sever; Muller Fabbri; Rodolfo Iuliano; Tiziana Palumbo; Flavia Pichiorri; Claudia Roldo; Ramiro Garzon; Cinzia Sevignani; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

8.  miR-15 and miR-16 induce apoptosis by targeting BCL2.

Authors:  Amelia Cimmino; George Adrian Calin; Muller Fabbri; Marilena V Iorio; Manuela Ferracin; Masayoshi Shimizu; Sylwia E Wojcik; Rami I Aqeilan; Simona Zupo; Mariella Dono; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-Gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-15       Impact factor: 11.205

9.  The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.

Authors:  Lorinda A Soma; Fiona E Craig; Steven H Swerdlow
Journal:  Hum Pathol       Date:  2006-01-10       Impact factor: 3.466

10.  Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.

Authors:  R Schroers; F Griesinger; L Trümper; D Haase; B Kulle; L Klein-Hitpass; L Sellmann; U Dührsen; J Dürig
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

View more
  1 in total

1.  Role of Bcl-2 -938 C>A polymorphism in susceptibility and prognosis of cancer: a meta-analysis.

Authors:  Xiao Zhang; Wenhao Weng; Wen Xu; Yulan Wang; Wenjun Yu; Xun Tang; Lifang Ma; Qiuhui Pan; Jiayi Wang; Fenyong Sun
Journal:  Sci Rep       Date:  2014-11-28       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.